Maintenance Chemotherapy for Advanced Non–Small-Cell Lung Cancer: New Life for an Old Idea

A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

(2017) V. A. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC).

(2017) C. P. Belani et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).

(2017) F. F. Kabbinavar et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer

(2012) Luis G. Paz-Ares et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer

(2012) Maurice Pérol et al.   JOURNAL OF CLINICAL ONCOLOGY

Progression-Free Survival: Meaningful or Simply Measurable?

(2012) Christopher M. Booth et al.   JOURNAL OF CLINICAL ONCOLOGY

Maintenance Therapy for Advanced Non–Small-Cell Lung Cancer: A Pilot Study on Patients’ Perceptions

(2012) Lies Peeters et al.   Journal of Thoracic Oncology

LATE-BREAKING ABSTRACTS

(2012) NA   Journal of Thoracic Oncology

Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study

(2012) Chandra P Belani et al.   LANCET ONCOLOGY

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial

(2012) Li Zhang et al.   LANCET ONCOLOGY

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

(2012) Luis Paz-Ares et al.   LANCET ONCOLOGY

Single agent maintenance therapy for advanced stage non-small cell lung cancer: A meta-analysis

(2012) Madhusmita Behera et al.   LUNG CANCER

Patients’ preferences for treatment outcomes for advanced non-small cell lung cancer: A conjoint analysis

(2012) John F.P. Bridges et al.   LUNG CANCER

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

(2012) Philip L. McCarthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer

(2012) David E. Gerber et al.   PATIENT EDUCATION AND COUNSELING

Maintenance Therapy With Continuous or Switch Strategy in Advanced Non-small Cell Lung Cancer

(2011) Xinji Zhang et al.   CHEST

AVAPERL (MO22089): Final Efficacy Outcomes for Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) Randomised to Continuation Maintenance (mtc) with Bevacizumab (bev) or Bev + Pemetrexed (pern) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx)

(2011) F Barlesi et al.   EUROPEAN JOURNAL OF CANCER

A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)

(2011) Rabab M. Gaafar et al.   EUROPEAN JOURNAL OF CANCER

Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer

(2011) Jamie L. Lesnock et al.   GYNECOLOGIC ONCOLOGY

Prospective Molecular Marker Analyses ofEGFRandKRASFrom a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer

(2011) Wolfram Brugger et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials

(2011) Liat Vidal et al.   JNCI-Journal of the National Cancer Institute

A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer

(2011) Mark J.C. Nuijten et al.   LUNG CANCER

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

(2011) Robert A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

(2011) Timothy J. Perren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

(2010) M. Reck et al.   ANNALS OF ONCOLOGY

Maintenance therapy in colon cancer

(2010) F. Giuliani et al.   CANCER TREATMENT REVIEWS

Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099

(2010) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Pem and the Cost of Multicycle Maintenance

(2010) Peter A. Learn et al.   Journal of Thoracic Oncology

Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer

(2010) Robert Klein et al.   Journal of Thoracic Oncology

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection of Patients for Maintenance Therapy

(2010) Jong-Mu Sun et al.   Journal of Thoracic Oncology

Predictors and Impact of Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer in the United States: Real-World Considerations for Maintenance Therapy

(2010) David E. Gerber et al.   Journal of Thoracic Oncology

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

(2010) Gilles Salles et al.   LANCET

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

(2010) Federico Cappuzzo et al.   LANCET ONCOLOGY

Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model

(2009) Claire Banissi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

(2009) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Duration of Chemotherapy for Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials

(2009) Yu Yang Soon et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Platinum-Doublet Chemotherapy Followed by Gefitinib Compared With Continued Platinum-Doublet Chemotherapy in Japanese Patients With Advanced Non–Small-Cell Lung Cancer: Results of a West Japan Thoracic Oncology Group Trial (WJTOG0203)

(2009) Koji Takeda et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

(2009) Robert Pirker et al.   LANCET

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

(2009) Tudor Ciuleanu et al.   LANCET

Redefining the Target Again: Chemotherapeutics as Vascular Disrupting Agents?

(2008) Yesim Gokmen-Polar et al.   CANCER CELL

Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: A systematic review with meta-analysis

(2008) João Paulo da Silveira Nogueira Lima et al.   EUROPEAN JOURNAL OF CANCER

Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology

(2008) Nasser Hanna et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023

(2008) Karen Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Giorgio Vittorio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer

(2008) Panos M. Fidias et al.   JOURNAL OF CLINICAL ONCOLOGY

An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard

(2008) Chris P. Lee et al.   VALUE IN HEALTH